Zegfrovy Sunvozertinib compound, a relatively new therapeutic agent, is generating significant interest within the neoplastic community. Its mechanism of action primarily involves selective inhibition of skin growth factor receptor (EGFR) tyrosine activity, showing promise in treating various cancerous forms. Initial clinical investigations have de